AZ, Daiichi Sankyo sign US Movantik deal
This article was originally published in Scrip
AstraZeneca is teaming up with Daiichi Sankyo, using the Japanese pharma's US-based sales teams and expertise in the primary care setting to commercialize its first-in-class mu-opioid receptor antagonist Movantik (naloxegol) in the US.
You may also be interested in...
Deal Snapshot: AstraZeneca has sublicensed global rights to its peripheral mu-opioid receptor antagonist to RedHill Biopharma, excluding Europe, Canada and Israel, with RedHill also separately receiving non-dilutive financing from HealthCare Royalty Partners.
Coaching and mentoring are important tools for the leaders of today to be able to foster the next generation of talent in the biopharma sector. While the routes into industry have not changed dramatically – most leaders hold a master’s degree and/or PhD – the expectations of rising leaders have altered and the industry itself has become more collaborative.
Angeli Möller, recently spotlighted by In Vivo as a 2020 Rising Leader, has quickly moved up the ranks at Bayer and is now spearheading one of its key initiatives to bring artificial intelligence and machine learning technologies into the pharma business.